首页|Hederacolchiside A1衍生物的合成及抗肿瘤活性研究

Hederacolchiside A1衍生物的合成及抗肿瘤活性研究

扫码查看
目的 设计并合成哌嗪酰化和哌嗪磺酰化hederacolchiside A1衍生物,测试其对肿瘤细胞的抗增殖活性.方法 采用半合成策略,在hederacolchiside A1的C-28位上引入磺酰化或甲酰化的哌嗪基团,同时在磺酰基和甲酰基上引入空间位阻大的芳香基团进行进一步结构修饰,得到两个系列的目标化合物(4a~4k和5a~5k).以苯甲酰化和乙酰化的hederacolchiside A1为起始原料,经亲电取代、亲核取代反应得到含哌嗪基团的关键中间体,该中间体与含不同取代基的苯磺酰氯进行缩合反应得到目标化合物4a~4k;与含不同取代基的苯甲酰氯进行缩合反应得到目标化合物5a~5k.采用MTT法评价目标化合物的体外抗肿瘤活性.结果 与结论设计并合成了 22个未见文献报道的新化合物,其结构均经ESI-MS、1H-NMR、13C-NMR谱确证.体外抗肿瘤活性测试结果表明,化合物5e对MCF-7肿瘤细胞表现出较强的抗增殖活性,其IC50值为(4.89± 0.09)μmol·L-1,优于阳性对照药 hederacolchiside A1[IC50=(19.36±0.48)µmol.L-1]和 5-氟尿嘧啶[IC50=(26.14±1.76)μmol·L-1],具有进一步研究的价值.
Synthesis and antitumor activity evaluation of hederacolchiside A1 derivatives
In order to discover new candidates with good antitumor activity,twenty-two compounds(4a-4k and 5a-5k)were designed and synthesized with hederacolchiside A1 as the lead compound using semi-synthetic strategy to introduce piperazine moieties at C-28.The structures of target compounds were confirmed by ESI-MS,1H-NMR and 13C-NMR.With hederacolchiside A1 and 5-fluorouracil as the positive control drugs,all target compounds were evaluated for in vitro antitumor activities against human tumor cell lines as HCT116,A549,HL-60 and MCF-7 using the MTT colorimetric assay.The results showed that most of the hederacolchiside A1 derivatives containing formylated piperazine structures showed varying degrees of anti-proliferative activities against the tested tumor cell lines.Compound 5e exhibited excellent anti-proliferation activity against MCF-7 cells with IC50 value of(4.89±0.09)µmol·L-1 compared with the positive control drugs,and it could be developed for further research.

saponinhederacolchiside A1antitumorstructural modification

孙子含、仲烨、程卯生、刘洋

展开 >

沈阳药科大学 基于靶点的药物设计与研究教育部重点实验室,辽宁沈阳 110016

三萜皂苷 hederacolchiside A1 抗肿瘤 结构改造

辽宁省高等学校创新人才支持计划项目

LR2017043

2024

中国药物化学杂志
沈阳药科大学,中国药学会

中国药物化学杂志

CSTPCD
影响因子:0.463
ISSN:1005-0108
年,卷(期):2024.34(1)
  • 14